Quick Answer
IMMUCELL CORP /DE/ reported Cash and Equivalents of $3.81 million for fiscal year 2025.
IMMUCELL CORP /DE/ Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $3.81M | +1.3% |
| 2024 | $3.76M | +284.0% |
| 2023 | $978.7K | -83.1% |
| 2022 | $5.79M | -43.1% |
| 2021 | $10.19M | +46.6% |
| 2020 | $6.95M | +10.4% |
| 2019 | $6.29M | +149.6% |
| 2018 | $2.52M | -33.6% |
| 2017 | $3.80M | -26.2% |
| 2016 | $5.15M | +227.4% |
| 2015 | $1.57M | +85.1% |
| 2014 | $850.0K | -62.6% |
| 2013 | $2.27M | -15.1% |
| 2012 | $2.67M | +242.1% |
| 2011 | $781.5K | -44.1% |
| 2010 | $1.40M | +43.4% |
| 2009 | $975.5K | -18.7% |
| 2008 | $1.20M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.89M | — | +3.4% |
| December 31, 2024 | $3.76M | +284.0% | +183.8% |
| June 30, 2024 | $1.32M | — | +37.9% |
| March 31, 2024 | $960.3K | -69.0% | -1.9% |
| December 31, 2023 | $978.7K | -83.1% | -50.8% |
| September 30, 2023 | $1.99M | -77.5% | -35.7% |
| March 31, 2023 | $3.10M | -73.8% | -46.5% |
| December 31, 2022 | $5.79M | -43.1% | -34.4% |
- IMMUCELL CORP /DE/ showed an increase of +1.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, IMMUCELL CORP /DE/’s cash and equivalents has grown by 217.3% (from $1.20 million to $3.81 million).
- The most recent figure is from IMMUCELL CORP /DE/’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: